No Data
lbx pharmacy chain joint stock (603883): Torch project helps increase gross margin. Deepening the expansion strategy of "advantages + sinking".
The company released the third quarter report of 2024: The revenue in the first three quarters of 2024 was 16.232 billion yuan, net income attributable to the parent company was 0.63 billion yuan, and non-recurring net income attributable to the parent company was 0.607 billion yuan, with year-on-year growth of 1.19% and -.
lbx pharmacy chain joint stock (603883): Gross margin steadily increasing, continuing to reduce costs and increase efficiency.
Core point On October 29, 2024, the company released its third-quarter performance report for 2024, achieving revenue of 16.232 billion yuan, a year-on-year increase of 1.19%, and achieving a net income attributable to the parent company of 0.63 billion yuan, year-on-year.
Donghai Securities: The chain pharmacy industry is accelerating consolidation, and the concentration continues to increase.
In 2023, the total market size of pharmaceutical stores is about 650 billion yuan, with a CAGR of 9.07% from 2015 to 2023. The retail pharmacy terminal sales scale accounts for 29.3% of the national pharmaceutical sales terminal.
Express News | lbx pharmacy chain joint stock: The current operation of the company is normal. There is no significant information that should be disclosed but has not been disclosed.
lbx pharmacy chain joint stock (603883) 2024 third quarter report review: preserve energy, enhance quality and efficiency
Subject: The company released the third quarter report of 2024, with revenue of 16.23 billion yuan (+1.2%), net income attributable to the parent company of 0.63 billion yuan (-12.1%), and non-net profit of 0.61 billion yuan (-5.9%). For the third quarter alone.
LBX pharmacy chain joint stock (603883): Performance under pressure, increasing profit margin is the focus of operation.
Ping An's opinion: Revenue growth slows down, performance under pressure. Due to factors such as weak consumer spending, access to outpatient visits, the company's revenue growth has slowed down on the income side, while on the other hand, the company's net margin is affected by accelerated expansion, newly opened stores still in the cultivation period, increased expense ratio, etc.
No Data
No Data